FDA to require vision loss warning on GLP-1 drug labels
The labelling requirement stems from the findings of a 2024 study and subsequent FDA trials that tested the results of that study.
We haven't written up this one. Global News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.